EquityFlow
›
Companies
› Aer Therapeutics
Aer Therapeutics
Biotech
· Raleigh, US
Inhaled small-molecule mucolytic drug for COPD
Funding history
Date
Round
Amount
Apr 2023
Series A
Irish-founded biopharma Aer Therapeutics (US-headquartered) closed a $36m Series A to advance its inhaled COPD mucolytic drug AER-01.
$36M
Investors
Canaan
Hatteras Venture Partners
OrbiMed
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →